Microcurrent Stimulation for Dry Age-related Macular Degeneration

Microcurrent Stimulation Therapy for Dry Age-related Macular Degeneration (i-SIGHT): a Multicenter, Randomized, Double-masked, Clinical Device Trial

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04511936

Acronym

i-SIGHT

Enrollment

Registered

2020-08-13

Start date

2021-03-01

Completion date

2023-01-31

Last updated

2021-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Age-related Macular Degeneration

Keywords

AMD, Dry AMD

Brief summary

Evaluate the safety and efficacy of microcurrent stimulation therapy for patients with dry age-related macular degeneration.

Detailed description

Multi-center, double-masked, randomized trial of microcurrent stimulation for the treatment of patients affected with dry age-related macular degeneration.

Interventions

DEVICEi-Lumen AMD

Microcurrent stimulator

DEVICEi-Lumen AMD Sham

Sham microcurrent stimulator

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

Key Inclusion Criteria - Study Eye: * Dry AMD diagnosis. Key

Exclusion criteria

- Study Eye: * Wet AMD

Design outcomes

Primary

Measure	Time frame
Mean change from baseline in best-corrected distance visual acuity (CDVA) at one month timepoint.	1 Month

Secondary

Measure	Time frame
Best-corrected distance visual acuity (CDVA) response rate at 1 month visit.	1 Month

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026